Skip to main content

Table 4 Medications Administered to Patients Over Two-Year Study Period

From: Analysis of urgent follow up visits and complications after intravitreal injections: a retrospective cohort study

N = 73,286

Medication

Frequency

Percentage

Aflibercept

44,191

60.3

Ranibizumab

16,416

22.4

Bevacizumab

9,820

13.4

Dexamethasone intravitreal implant

1,466

2

Triamcinolone acetonide

1,173

1.6

Brolucizumab

1,165

1.59

Fluocinolone acetonide intravitreal implant .19 mg

147

0.2

Fluocinolone acetonide intravitreal implant .18 mg

22

0.03